Pipeline

Our goal is to be the leading biopharmaceutical company developing and marketing therapies that restore function and improve the lives of people with multiple sclerosis (MS), spinal cord injury (SCI) and other neurological conditions.

Acorda’s R&D efforts are designed to:

  • Exploring the use of AMPYRA® (dalfampridine), which is currently approved in the United States to improve walking in people with multiple sclerosis (MS), to address other functional impairments caused by MS
  • Conducting research to determine if AMPYRA is a therapeutic option for post-stroke deficits
  • Clinical development of AC105 as a treatment in acute spinal cord injury
  • Clinical development of GGF2 for the treatment of heart failure; Acorda is also studying GGF2 as a potential treatment in several neurological applications
  • Advancing other clinical and preclinical stage products in our pipeline, which have potential therapeutic value in neurological conditions such as MS, spinal cord injury, stroke, and traumatic brain injury
Click on a therapy for more information
Therapy    R&D    Pre Clinical Phase 1 Phase 2 Phase 3/4 Marketed
AMPYRA®
Walking in MS
 
 
 
 
 
 
DALFAMPRIDINE
Post-Stroke Walking Deficits
 
 
 
 
 
 
ZANAFLEX®
Spasticity
 
 
 
 
 
 
QUTENZA®
Post-Shingles Nerve Pain
 
 
 
 
 
 
NP-1998
Neuropathic Pain
 
 
 
 
 
 
PLUMIAZ
Cluster Seizures
 
 
 
 
 
 
GGF2
Heart Failure
 
 
 
 
 
 
Stroke/SCI/PNI
 
 
 
 
 
 
rHlgM22
MS
 
 
 
 
 
 
AC105
SCI
 
 
 
 
 
 
CHONDROITINASE
SCI